AgeX Therapeutics (AgeX Therapeutics) GF Value : $33.41 (As of May. 23, 2024)

View and export this data going back to 2018. Start your Free Trial

What is AgeX Therapeutics GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-23), AgeX Therapeutics's share price is $11.10. AgeX Therapeutics's GF Value is $33.41. Therefore, AgeX Therapeutics's Price-to-GF-Value for today is 0.33.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes AgeX Therapeutics is Possible Value Trap, Think Twice.

AgeX Therapeutics (AMEX:AGE) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

AgeX Therapeutics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	11.10	/	33.41
	=	0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgeX Therapeutics GF Value Related Terms

Thank you for viewing the detailed overview of AgeX Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

AgeX Therapeutics (AgeX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AgeX Therapeutics Inc (AMEX:AGE) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

0X4:Germany 0X4:Germany

Address

1101 Marina Village Parkway, Suite 201, Alameda, CA, USA, 94501

Website

https://www.agexinc.com

AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develops medicines designed to address some of the unsolved problems in aging. Its PureStem-derived cell-based therapeutic candidates in development are AGEX-VASC1, AGEX-BAT1 and AGEX-iTR1547.

Executives

Jean-christophe Renondin	director	505 PARK AVENUE 14TH FLOOR, NEW YORK NY 10022
Juvenescence Us Corp.	director, 10 percent owner	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Joanne M. Hackett	director	C/O AGEX THERAPEUTICS, INC.,, 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94708
Park Andrea Eun Jae	officer: Chief Financial Officer	C/O AGEX THERAPEUTICS, INC., 965 ATLANTIC AVE., SUITE 101, ALAMEDA CA 94501
Michael H May	director	965 ATLANTIC AVENUE, SUITE 101, ALAMEDA CA 94501
Michael D West	director, officer: Chief Executive Officer	AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501
Michael H. Mulroy	director	1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Russell Skibsted	officer: Chief Financial Officer	15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Judith Segall	officer: Corporate Secretary	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Hal Sternberg	officer: Vice President-Research	935 PARDEE STREET, BERKELEY CA 94710
Annalisa Jenkins	director	C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
John F Mauldin	director	3204 BEVERLY DRIVE, DALLAS TX 75205
Gregory Bailey	director	4 A CHESHAM STREET, LONDON X0 SW1X8DT
Juvenescence Ltd	10 percent owner	1ST FLOOR, VIKING HOUSE, ST PAULS SQUARE, RAMSEY Y8 IM8 1GB
Nafees Naseer Malik	officer: Chief Operating Officer	C/O AGEX THERAPEUTICS, INC., 1010 ATLANTIC AVE, STE 102, ALAMEDA CA 94501